Top

BY Scott Merville

A targeted therapy resurrected by the Moon Shots Program™ at MD Anderson has produced unprecedented response rates among patients with metastatic non-small cell lung cancer that carries a highly treatment-resistant mutation.

In a Phase II clinical trial, the drug poziotinib has shrunk tumors by at least 30% in eight of 11 (73%) non-small cell lung cancer patients whose cancer includes an epidermal growth factor receptor...

John Heymach lung cancer

BY Scott Merville

A major national effort to expand the reach of cancer immunotherapy in order to benefit more patients will draw upon the expertise...

BY Kathryn Boom

In Texas, the number is even lower. Only 33% of Texas teens were up to date. That’s a lot of room for improvement.

Having spent the...

BY Scott Merville

Deeply entrenched and mature by the time it’s found, pancreatic cancer is one of the hardest types of the disease to defeat. A Dream Team assembled by Stand Up to Cancer and led by an investigator at MD Anderson Cancer Center will test new ways to find the disease in its emerging, more vulnerable phase in people who are at high risk for developing it.

“Our plan is to intercept pancreatic cancer by finding it and stopping it before...

 Anirban Maitra, M.B.B.S., will lead a Dream Team assembled by Stand Up to Cancer to deploy universal testing for inherited mutations in pancreatic cancer patients, apply deep machine learning to improve imaging, tailor vaccines to knock down emerging disease and sift the best ideas to develop blood tests for predicting risk and detecting precursor or early disease.

BY Clayton Boldt, Ph.D.

It's been five years since MD Anderson launched its Moon Shots Program™, a collaborative effort to more quickly turn scientific discoveries...

BY Ronda Wendler

The effectiveness of opioids in treating cancer pain has been well established over the years. But today’s opioid epidemic that began slowly...